tried to start a new thread for this, looks like the big boys are heading into PAB territory!?
NEW YORK -- Pfizer says it will partner with German drug and chemical maker Merck in developing potential cancer drugs in a hot new medication class that harnesses the body's immune system to fight cancer.
Under their agreement, New York-based Pfizer will pay Merck KGaA $850 million initially and up to $2 billion total, based on how many drugs are approved and future revenue.
The two companies plan to develop drugs to fight multiple cancer types, either alone or in combination with their other cancer treatments. They say they expect next year to start up to 20 patient testing programs of such immuno-oncology drugs.
Associated Press
Published Monday, November 17, 2014 2:19PM EST
Ann: Patrys 2014 AGM Presentation, page-27
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.002(33.3%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $95.25K | 26.45M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 29109964 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 19424458 | 8 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |